FY2025 EPS Estimates for Sanara MedTech Lowered by Analyst

Sanara MedTech Inc. (NASDAQ:SMTI) – Equities researchers at Cantor Fitzgerald reduced their FY2025 earnings per share estimates for shares of Sanara MedTech in a note issued to investors on Wednesday, March 26th. Cantor Fitzgerald analyst R. Osborn now anticipates that the company will earn ($2.43) per share for the year, down from their prior forecast of ($0.98). Cantor Fitzgerald currently has a “Overweight” rating and a $46.00 price target on the stock. The consensus estimate for Sanara MedTech’s current full-year earnings is ($1.10) per share.

Separately, HC Wainwright increased their price target on shares of Sanara MedTech from $50.00 to $51.00 and gave the company a “buy” rating in a research report on Wednesday.

Sanara MedTech Price Performance

Shares of NASDAQ SMTI opened at $30.19 on Friday. The company has a current ratio of 2.23, a quick ratio of 2.02 and a debt-to-equity ratio of 0.76. The company’s 50-day moving average price is $34.26 and its 200 day moving average price is $33.74. Sanara MedTech has a 52 week low of $26.00 and a 52 week high of $39.08. The stock has a market cap of $263.89 million, a price-to-earnings ratio of -30.49 and a beta of 1.37.

Sanara MedTech (NASDAQ:SMTI) last posted its earnings results on Tuesday, March 25th. The company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.01. The company had revenue of $26.31 million for the quarter, compared to analyst estimates of $22.75 million. Sanara MedTech had a negative return on equity of 19.86% and a negative net margin of 10.71%.

Institutional Trading of Sanara MedTech

A number of large investors have recently made changes to their positions in SMTI. State Street Corp lifted its holdings in Sanara MedTech by 9.2% in the 3rd quarter. State Street Corp now owns 58,688 shares of the company’s stock valued at $1,775,000 after purchasing an additional 4,932 shares in the last quarter. Barclays PLC lifted its stake in shares of Sanara MedTech by 323.0% during the third quarter. Barclays PLC now owns 5,731 shares of the company’s stock valued at $174,000 after buying an additional 4,376 shares during the period. Geode Capital Management LLC boosted its position in Sanara MedTech by 4.4% during the third quarter. Geode Capital Management LLC now owns 88,271 shares of the company’s stock worth $2,670,000 after acquiring an additional 3,755 shares during the last quarter. JPMorgan Chase & Co. grew its stake in Sanara MedTech by 127.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 4,058 shares of the company’s stock worth $123,000 after acquiring an additional 2,272 shares during the period. Finally, Fifth Third Bancorp acquired a new position in Sanara MedTech in the 4th quarter valued at $898,000. Institutional investors and hedge funds own 8.10% of the company’s stock.

Sanara MedTech Company Profile

Sanara MedTech Inc, a medical technology company, develops, markets, and distributes surgical, wound, and skincare products and services to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical, a medical hydrolysate of Type I bovine collagen indicated for the management of surgical, traumatic, and partial- and full-thickness wounds, as well as first- and second-degree burns; and HYCOL, a medical hydrolysate of Type I bovine collagen intended for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers.